APA
Ruiz Rodríguez, María Jesús & Oller, Jorge & Martínez Martínez, Sara & Alarcón Ruiz, Iván & Toral, Marta & Sun, Yilin & Colmenar, Ángel & Méndez Olivares, María José & López Maderuelo, Dolores & Kern, Christine B & Nistal, J. Francisco & Evangelista, Arturo & Teixido Tura, Gisela & Campanero, Miguel R & Redondo, Juan Miguel (2024-01 ) .Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation.
ISO 690
Ruiz Rodríguez, María Jesús & Oller, Jorge & Martínez Martínez, Sara & Alarcón Ruiz, Iván & Toral, Marta & Sun, Yilin & Colmenar, Ángel & Méndez Olivares, María José & López Maderuelo, Dolores & Kern, Christine B & Nistal, J. Francisco & Evangelista, Arturo & Teixido Tura, Gisela & Campanero, Miguel R & Redondo, Juan Miguel. 2024-01 .Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation.
https://hdl.handle.net/20.500.12080/45183
Résumé:
Thoracic aortic aneurysm and dissection (TAAD) is a life-threatening
condition associated with Marfan syndrome (MFS), a disease caused
by fibrillin-1 gene mutations. While various conditions causing TAAD
exhibit aortic accumulation of the proteoglycans versican (Vcan) and
aggrecan (Acan), it is unclear whether these ECM proteins are
involved in aortic disease. Here, we find that Vcan, but not Acan,
accumulated in Fbn1C1041G/+ aortas, a mouse model of MFS. Vcan
haploinsufficiency protected MFS mice against aortic dilation, and its
silencing reverted aortic disease by reducing Nos2 protein expression.
Our results suggest that Acan is not an essential contributor to MFS
aortopathy. We further demonstrate that Vcan triggers Akt activation
and that pharmacological Akt pathway inhibition rapidly regresses
aortic dilation and Nos2 expression in MFS mice. Analysis of aortic
tissue from MFS human patients revealed accumulation of VCAN and
elevated pAKT-S473 staining. Together, these findings reveal
that Vcan plays a causative role in MFS aortic disease in vivo by
inducing Nos2 via Akt activation and identify Akt signaling pathway
components as candidate therapeutic targets.